In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Chimeric antigen receptor T cell (CAR-T cell) therapy has shown impressive success in the treatment of hematological malignancies, but the systemic toxicity and complex manufacturing process of current autologous CAR-T cell therapy hinder its broader applications. Universal CAR-T cells have been developed to simplify the production process through isolation and editing of allogeneic T cells from healthy persons, but the allogeneic CAR-T cells have recently encountered safety concerns, and clinical trials have been halted by the FDA. Thus, there is an urgent need to seek new ways to overcome the barriers of current CAR-T cell therapy. In-vivo CAR-T cells induced by nanocarriers loaded with CAR-genes and gene-editing tools have shown efficiency for regressing leukemia and reducing systemic toxicity in a mouse model. The in-situ programming of autologous T-cells avoids the safety concerns of allogeneic T cells, and the manufacture of nanocarriers can be easily standardized. Therefore, the in-vivo induced CAR-T cells can potentially overcome the abovementioned limitations of current CAR-T cell therapy. Here, we provide a review on CAR structures, gene-editing tools, and gene delivery techniques applied in immunotherapy to help design and develop new in-vivo induced CAR-T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, LNPs are being explored for in vivo CAR T cell generation, which would eliminate the need for any ex vivo cell manipulation, potentially reducing manufacturing time and increasing accessibility by delivering health-economic benefits.31,44,51”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [51]
In the citing paper
“They are associated with lower cytotoxicity and offer potential for in vivo use.31,44,51”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [51]
In the citing paper
“In contrast, LNP’s mRNA payload is delivered to and translated in the cytoplasm only upon endosomal uptake and release, as well as LNP disintegration.34,51”
From Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation (2026) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“Especially, lipid-based nanoparticles have recently been successfully used to deliver SARS-CoV-2 mRNA vaccines (106).”
MethodEngineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
A TALE nuclease architecture for efficient genome editing
Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., Leung, E., Hinkley, S. J., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1755 · Cited by 2,098 · cited 1×
“TALEN are composed of several TAL units that can recognize base pairs of DNA and link to an endonuclease to generate the site-specific cleavage of DNAs (86, 87).”
BackgroundRNA-guided genetic silencing systems in bacteria and archaea
Wiedenheft, B., Sternberg, S. H., & Doudna, J. A. (2012) · Nature · doi:10.1038/nature10886 · Cited by 1,851 · cited 2×
“Once the Cas–crRNA complex recognizes a homologous protospacer and PAM sequence, the Cas endonuclease cleaves the double-stranded DNA, followed by an automatic DNA repair process (88).”
BackgroundTargeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406 · cited 1×
“CRS often causes fever, hypotension, hypoxia, organ dysfunction, and even lifethreatening adverse reactions (8, 64, 65).”
BackgroundCAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Finn, J. D., Smith, A. R., Patel, M. C., Shaw, L., Youniss, M. R., van Heteren, J., Dirstine, T., Ciullo, C., Lescarbeau, R., Seitzer, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.014 · Cited by 878 · cited 1×
“Lipid nanoparticles have also been used to deliver the CRISPR/Cas9 system to achieve in-vivo genome editing at clinically relevant levels (107, 108).”
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852 · cited 1×
“The CAR structure is continually evolving to improve the efficacy of current CAR-T cell therapy (32, 49).”
BackgroundChimeric nucleases stimulate gene targeting in human cells
Porteus, M. H., & Baltimore, D. (2003) · Science · doi:10.1126/science.1078395 · Cited by 741 · cited 1×
“Multimeric zinc finger proteins are able to link with the FokI endonuclease to create a ZFN that can cleave site-specific double-stranded DNA and lead to homologous recombination (HR) or nonhomologous end-joining (NHEJ) (85).”
BackgroundZhang, C., Liu, J., Zhong, J. F., & Zhang, X. (2017) · Biomarker Research · doi:10.1186/s40364-017-0102-y · Cited by 578
Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers
Prasad, V. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.156 · Cited by 229
Freyer, C. W., & Porter, D. L. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.025 · Cited by 216
Manufacturing chimeric antigen receptor T cells: issues and challenges
Roddie, C., O'Reilly, M., Dias Alves Pinto, J., Vispute, K., & Lowdell, M. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2018.11.009 · Cited by 168
Current status and perspectives of genome editing technology for microalgae
Jeon, S., Lim, J.-M., Lee, H.-G., Shin, S.-E., Kang, N. K., Park, Y.-I., Oh, H.-M., Jeong, W.-J., Jeong, B.-R., & Chang, Y. K. (2017) · Biotechnology for Biofuels · doi:10.1186/s13068-017-0957-z · Cited by 154
Engineering chimeric antigen receptor-T cells for cancer treatment
Ye, B., Stary, C. M., Li, X., Gao, Q., Kang, C., & Xiong, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0814-0 · Cited by 95
Research works printed but not linked: 116
- Ramos, 2016, CAR-T Cell Therapy for Lymphoma, Annu Rev Med, 67, 10.1146/annurev-med-051914-021702 · DOI · Paper page
- Mohanty, 2019, CAR T Cell Therapy: A New Era for Cancer Treatment (Review), Oncol Rep, 42, 10.3892/or.2019.7335 · DOI · Paper page
- Fiorenza, 2021, CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success, BioDrugs, 35, 281, 10.1007/s40259-021-00477-8 · DOI
- Kersten, 2020, CD19-Directed CAR T-Cell Therapy in B-Cell NHL, Curr Opin Oncol, 32, 10.1097/CCO.0000000000000668 · DOI
- Qualls, 2021, Optimizing CAR T Cell Therapy in Lymphoma, Hematol Oncol, 39, 10.1002/hon.2844 · DOI
- Sheth, 2021, Taming the Beast: CRS and ICANS After CAR T-Cell Therapy for ALL, Bone Marrow Transplant, 56, 10.1038/s41409-020-01134-4 · DOI · Paper page
- Xu, 2018, Toward Precision Manufacturing of Immunogene T-Cell Therapies, Cytotherapy, 20, 10.1016/j.jcyt.2017.12.007 · DOI
- Nawaz, 2020, Nanotechnology and Immunoengineering: How Nanotechnology can Boost CAR-T Therapy, Acta Biomater, 109, 21, 10.1016/j.actbio.2020.04.015 · DOI
- Gong, 2021, Nanomaterials for T-Cell Cancer Immunotherapy, Nat Nanotechnol, 16, 25, 10.1038/s41565-020-00822-y · DOI · Paper page
- Zhao, 2018, Universal CARs, Universal T Cells, and Universal CAR T Cells, J Hematol Oncol, 11, 132, 10.1186/s13045-018-0677-2 · DOI · Paper page
- Perez, 2020, Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells, Front Immunol, 11, 10.3389/fimmu.2020.583716 · DOI
- Townsend, 2020, Paving the Way Towards Universal Treatment With Allogenic T Cells, Immunol Res, 68, 63, 10.1007/s12026-020-09119-7 · DOI
- Wagner, 2021, Immunogenicity of CAR T Cells in Cancer Therapy, Nat Rev Clin Oncol, 18, 10.1038/s41571-021-00476-2 · DOI · Paper page
- Graham, 2018, Allogeneic CAR-T Cells: More Than Ease of Access, Cells, 7, 155, 10.3390/cells7100155 · DOI · Paper page
- Locke, 2021, First-In-Human Data of ALLO-501A, an Allogeneic Chimeric Antigen Receptor (CAR) T-Cell Therapy and ALLO-647 in Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): ALPHA2 Study, J Clin Oncol, 39, 10.1200/JCO.2021.39.15_suppl.2529 · doi:10.1200/jco.2021.39.15_suppl.2529
- Smith, 2017, In Situ Programming of Leukaemia-Specific T Cells Using Synthetic DNA Nanocarriers, Nat Nanotechnol, 12, 10.1038/nnano.2017.57 · DOI · Paper page
- Agarwal, 2020, In Vivo Generation of CAR T Cells Selectively in Human CD4(+) Lymphocytes, Mol Ther, 28, 10.1016/j.ymthe.2020.05.005 · DOI · Paper page
- Parayath, 2020, In Vitro-Transcribed Antigen Receptor mRNA Nanocarriers for Transient Expression in Circulating T Cells In Vivo, Nat Commun, 11, 6080, 10.1038/s41467-020-19486-2 · DOI · Paper page
- Mhaidly, 2019, The Future: In Vivo CAR T Cell Gene Therapy, Mol Ther, 27, 10.1016/j.ymthe.2019.03.012 · DOI
- Chandran, 2019, T Cell Receptor-Based Cancer Immunotherapy: Emerging Efficacy and Pathways of Resistance, Immunol Rev, 290, 10.1111/imr.12772 · DOI · Paper page
- Huang, 2020, Recent Advances in CAR-T Cell Engineering, J Hematol Oncol, 13, 86, 10.1186/s13045-020-00910-5 · DOI · Paper page
- Muhammad, 2017, CAR T-Cells for Cancer Therapy, Biotechnol Genet Eng Rev, 33, 190, 10.1080/02648725.2018.1430465 · DOI
- Schwarzbich, 2017, Cellular Immunotherapy in B-Cell Malignancy, Oncol Res Treat, 40, 10.1159/000481946 · DOI
- Zenere, 2019, Optimizing Intracellular Signaling Domains for CAR NK Cells in HIV Immunotherapy: A Comprehensive Review, Drug Discov Today, 24, 10.1016/j.drudis.2019.02.002 · DOI
- Jayaraman, 2020, CAR-T Design: Elements and Their Synergistic Function, EBioMedicine, 58, 10.1016/j.ebiom.2020.102931 · DOI · Paper page
- Zhang, 2020, CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead, J Immunol Res, 2020, 10.1155/2020/1924379 · DOI
- Wang, 2017, New Development in CAR-T Cell Therapy, J Hematol Oncol, 10, 53, 10.1186/s13045-017-0423-1 · DOI · Paper page
- Brudno, 2019, Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management, Blood Rev, 34, 45, 10.1016/j.blre.2018.11.002 · DOI · Paper page
- Tokarew, 2019, Teaching an Old Dog New Tricks: Next-Generation CAR T Cells, Br J Cancer, 120, 26, 10.1038/s41416-018-0325-1 · DOI · Paper page
- Moreno-Cortes, 2021, Chimeric Antigen Receptor T Cell Therapy in Oncology - Pipeline at a Glance: Analysis of the ClinicalTrials.gov Database, Crit Rev Oncol Hematol, 159, 10.1016/j.critrevonc.2021.103239 · DOI
- Kim, 2020, Recent Advances in Allogeneic CAR-T Cells, Biomolecules, 10, 263, 10.3390/biom10020263 · DOI
- Weinkove, 2019, Selecting Costimulatory Domains for Chimeric Antigen Receptors: Functional and Clinical Considerations, Clin Transl Immunol, 8, 10.1002/cti2.1049 · DOI · Paper page
- Albinger, 2021, Current Status and Perspective of CAR-T and CAR-NK Cell Therapy Trials in Germany, Gene Ther, 28, 10.1038/s41434-021-00246-w · DOI · Paper page
- 2016, From CARs to TRUCKs and Beyond: Safely En Route to Adoptive T-Cell Therapy for Cancer, EBioMedicine, 14, 1, 10.1016/j.ebiom.2016.11.037 · DOI
- Dragon, 2020, CAR-T Cells and TRUCKs That Recognize an EBNA-3C-Derived Epitope Presented on HLA-B*35 Control Epstein-Barr Virus-Associated Lymphoproliferation, J Immunother Cancer, 8, 10.1136/jitc-2020-000736 · DOI
- Hombach, 2016, Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-Cell Attack, Mol Ther, 24, 10.1038/mt.2016.82 · DOI
- Sentman, 2016, Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice, J Immunol, 197, 10.4049/jimmunol.1600769 · DOI · Paper page
- Teeling, 2006, The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20, J Immunol, 177, 10.4049/jimmunol.177.1.362 · DOI · Paper page
- Rose, 1999, Critical Lym-1 Binding Residues on Polymorphic HLA-DR Molecules, Mol Immunol, 36, 10.1016/S0161-5890(99)00083-8 · doi:10.1016/s0161-5890(99)00083-8
- Scarfò, 2018, Anti-CD37 Chimeric Antigen Receptor T Cells are Active Against B- and T-Cell Lymphomas, Blood, 132, 10.1182/blood-2018-04-842708 · DOI
- Köksal, 2019, Preclinical Development of CD37CAR T-Cell Therapy for Treatment of B-Cell Lymphoma, Blood Adv, 3, 10.1182/bloodadvances.2018029678 · DOI
- Ormhøj, 2019, Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma With or Without Cotargeting CD19, Clin Cancer Res, 25, 10.1158/1078-0432.CCR-19-1337 · DOI
- Ruella, 2017, Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells, Cancer Discov, 7, 10.1158/2159-8290.CD-16-0850 · DOI · Paper page
- Roselli, 2021, Insight Into Next-Generation CAR Therapeutics: Designing CAR T Cells to Improve Clinical Outcomes, J Clin Invest, 131, 10.1172/JCI142030 · DOI
- Roberts, 2018, Axicabtagene Ciloleucel, a First-in-Class CAR T Cell Therapy for Aggressive NHL, Leuk Lymphoma, 59, 10.1080/10428194.2017.1387905 · DOI · Paper page
- Abramson, 2020, Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma, Transfus Med Rev, 34, 29, 10.1016/j.tmrv.2019.08.003 · DOI
- Anderson, 2021, Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Mantle Cell Lymphoma, Ann Pharmacother, 2, 10.1177/10600280211026338 · DOI
- Mikkilineni, 2021, CAR T Cell Therapies for Patients With Multiple Myeloma, Nat Rev Clin Oncol, 18, 71, 10.1038/s41571-020-0427-6 · DOI · Paper page
- Pettitt, 2018, CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape, Mol Ther, 26, 10.1016/j.ymthe.2017.10.019 · DOI
- Vitale, 2020, CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences, Front Oncol, 10, 10.3389/fonc.2020.00849 · DOI
- Wei, 2021, Clinical Development of CAR T Cell Therapy in China: 2020 Update, Cell Mol Immunol, 18, 792, 10.1038/s41423-020-00555-x · DOI
- Marple, 2020, Improving CAR T-Cells: The Next Generation, Semin Hematol, 57, 10.1053/j.seminhematol.2020.07.002 · DOI
- Rafiq, 2020, Engineering Strategies to Overcome the Current Roadblocks in CAR T Cell Therapy, Nat Rev Clin Oncol, 17, 10.1038/s41571-019-0297-y · DOI · Paper page
- Schubert, 2021, Side-Effect Management of Chimeric Antigen Receptor (CAR) T-Cell Therapy, Ann Oncol, 32, 34, 10.1016/j.annonc.2020.10.478 · DOI · Paper page
- Anderson, 2019, A Review of Chimeric Antigen Receptor T-Cells in Lymphoma, Expert Rev Hematol, 12, 10.1080/17474086.2019.1629901 · DOI
- Neelapu, 2019, Managing the Toxicities of CAR T-Cell Therapy, Hematol Oncol, 37, 48, 10.1002/hon.2595 · DOI · Paper page
- Gust, 2020, Cytokines in CAR T Cell-Associated Neurotoxicity, Front Immunol, 11, 10.3389/fimmu.2020.577027 · DOI · Paper page
- Ying, 2019, A Safe and Potent Anti-CD19 CAR T Cell Therapy, Nat Med, 25, 10.1038/s41591-019-0421-7 · DOI · Paper page
- Kennedy, 2020, A Review of Cancer Immunotherapy Toxicity, CA Cancer J Clin, 70, 86, 10.3322/caac.21596 · DOI · Paper page
- Tallantyre, 2021, Neurological Updates: Neurological Complications of CAR-T Therapy, J Neurol, 268, 10.1007/s00415-020-10237-3 · DOI
- Yu, 2019, Next Generation Chimeric Antigen Receptor T Cells: Safety Strategies to Overcome Toxicity, Mol Cancer, 18, 125, 10.1186/s12943-019-1057-4 · DOI · Paper page
- Castellarin, 2020, A Rational Mouse Model to Detect on-Target, Off-Tumor CAR T Cell Toxicity, JCI Insight, 5, 10.1172/jci.insight.136012 · DOI
- Parker, 2020, Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies, Cell, 183, 126, 10.1016/j.cell.2020.08.022 · DOI · Paper page
- Derlin, 2021, (18)F-FDG PET/CT of Off-Target Lymphoid Organs in CD19-Targeting Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Ann Nucl Med, 35, 10.1007/s12149-020-01544-w · DOI
- Hou, 2021, Navigating CAR-T Cells Through the Solid-Tumour Microenvironment, Nat Rev Drug Discov, 20, 10.1038/s41573-021-00189-2 · DOI · Paper page
- Martinez, 2019, CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment, Front Immunol, 10, 10.3389/fimmu.2019.00128 · DOI · Paper page
- Wagner, 2020, CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality, Mol Ther, 28, 10.1016/j.ymthe.2020.09.015 · DOI · Paper page
- Vormittag, 2018, A Guide to Manufacturing CAR T Cell Therapies, Curr Opin Biotechnol, 53, 10.1016/j.copbio.2018.01.025 · DOI · Paper page
- Stock, 2019, Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy, Int J Mol Sci, 20, 6223, 10.3390/ijms20246223 · DOI
- Bak, 2018, Gene Editing on Center Stage, Trends Genet, 34, 10.1016/j.tig.2018.05.004 · DOI · Paper page
- Li, 2020, Applications of Genome Editing Technology in the Targeted Therapy of Human Diseases: Mechanisms, Advances and Prospects, Signal Transduct Target Ther, 5, 1, 10.1038/s41392-019-0089-y · DOI · Paper page
- Urnov, 2005, Highly Efficient Endogenous Human Gene Correction Using Designed Zinc-Finger Nucleases, Nature, 435, 10.1038/nature03556 · DOI · Paper page
- Chandrasegaran, 2017, Recent Advances in the Use of ZFN-Mediated Gene Editing for Human Gene Therapy, Cell Gene Ther Insights, 3, 33, 10.18609/cgti.2017.005 · DOI
- Boch, 2009, Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors, Science, 326, 10.1126/science.1178811 · DOI · Paper page
- Barrangou, 2017, A Decade of Discovery: CRISPR Functions and Applications, Nat Microbiol, 2, 17092, 10.1038/nmicrobiol.2017.92 · DOI · Paper page
- Mali, 2013, RNA-Guided Human Genome Engineering via Cas9, Science, 339, 10.1126/science.1232033 · DOI · Paper page
- Ren, 2017, A Versatile System for Rapid Multiplex Genome-Edited CAR T Cell Generation, Oncotarget, 8, 10.18632/oncotarget.15218 · DOI · Paper page
- Gomes-Silva, 2017, CD7-Edited T Cells Expressing a CD7-Specific CAR for the Therapy of T-Cell Malignancies, Blood, 130, 10.1182/blood-2017-01-761320 · DOI · Paper page
- Borot, 2019, Gene-Edited Stem Cells Enable CD33-Directed Immune Therapy for Myeloid Malignancies, Proc Natl Acad Sci USA, 116, 10.1073/pnas.1819992116 · DOI
- Liu, 2017, CRISPR-Cas9-Mediated Multiplex Gene Editing in CAR-T Cells, Cell Res, 27, 10.1038/cr.2016.142 · DOI · Paper page
- Li, 2020, Applications and Explorations of CRISPR/Cas9 in CAR T-Cell Therapy, Brief Funct Genomics, 19, 10.1093/bfgp/elz042 · DOI
- Hu, 2021, Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies, Curr Med Sci, 41, 10.1007/s11596-021-2391-5 · DOI
- Razeghian, 2021, A Deep Insight Into CRISPR/Cas9 Application in CAR-T Cell-Based Tumor Immunotherapies, Stem Cell Res Ther, 12, 428, 10.1186/s13287-021-02510-7 · DOI
- David, 2017, Viral Vectors: The Road to Reducing Genotoxicity, Toxicol Sci, 155, 10.1093/toxsci/kfw220 · DOI · Paper page
- Monjezi, 2017, Enhanced CAR T-Cell Engineering Using non-Viral Sleeping Beauty Transposition From Minicircle Vectors, Leukemia, 31, 10.1038/leu.2016.180 · DOI · Paper page
- Shi, 2018, A Review on Electroporation-Based Intracellular Delivery, Molecules, 23, 3044, 10.3390/molecules23113044 · DOI · Paper page
- Zhang, 2018, Optimized DNA Electroporation for Primary Human T Cell Engineering, BMC Biotechnol, 18, 4, 10.1186/s12896-018-0419-0 · DOI
- Chen, 2018, An Artificial Molecular Shuttle Operates in Lipid Bilayers for Ion Transport, J Am Chem Soc, 140, 10.1021/jacs.8b09580 · doi:10.1021/jacs.8b09580
- Rajpoot, 2019, Solid Lipid Nanoparticles: A Promising Nanomaterial in Drug Delivery, Curr Pharm Des, 25, 10.2174/1381612825666190903155321 · DOI
- Eygeris, 2020, Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery, Nano Lett, 20, 10.1021/acs.nanolett.0c01386 · DOI · Paper page
- Wei, 2020, Systemic Nanoparticle Delivery of CRISPR-Cas9 Ribonucleoproteins for Effective Tissue Specific Genome Editing, Nat Commun, 11, 3232, 10.1038/s41467-020-17029-3 · DOI · Paper page
- Meneksedag-Erol, 2015, Probing the Effect of miRNA on siRNA-PEI Polyplexes, J Phys Chem B, 119, 10.1021/acs.jpcb.5b00415 · DOI
- Ita, 2020, Polyplexes for Gene and Nucleic Acid Delivery: Progress and Bottlenecks, Eur J Pharm Sci, 150, 10.1016/j.ejps.2020.105358 · doi:10.1016/j.ejps.2020.105358
- Kazemi Oskuee, 2018, Investigating the Influence of Polyplex Size on Toxicity Properties of Polyethylenimine Mediated Gene Delivery, Life Sci, 197, 10.1016/j.lfs.2018.02.008 · DOI
- Hayat, 2019, Gene Delivery Using Lipoplexes and Polyplexes: Principles, Limitations and Solutions, Crit Rev Eukaryot Gene Expr, 29, 29, 10.1615/CritRevEukaryotGeneExpr.2018025132 · DOI
- Gao, 2018, Exosomes in Cancer Therapy: A Novel Experimental Strategy, Am J Cancer Res, 8
- Dutta, 2021, Exosomes-Based Cell-Free Cancer Therapy: A Novel Strategy for Targeted Therapy, Immunol Med, 44, 10.1080/25785826.2020.1818482 · DOI
- Koritzinsky, 2017, Quantification of Exosomes, J Cell Physiol, 232, 10.1002/jcp.25387 · DOI · Paper page
- Wu, 2019, Cell Membrane Camouflaged Nanoparticles: A New Biomimetic Platform for Cancer Photothermal Therapy, Int J Nanomed, 14, 10.2147/IJN.S200284 · DOI
- Spanjers, 2020, Cell Membrane Coated Particles, Adv Biosyst, 4, 10.1002/adbi.202000174 · DOI
- Wang, 2020, Cell Membrane Biomimetic Nanoparticles for Inflammation and Cancer Targeting in Drug Delivery, Biomater Sci, 8, 10.1039/C9BM01392J · DOI · Paper page
- Smith, 2020, CAR-T Cell Expansion in a Xuri Cell Expansion System W25, Methods Mol Biol, 2086, 10.1007/978-1-0716-0146-4_11 · DOI
- Geethakumari, 2021, Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments, Curr Hematol Malig Rep, 16, 10.1007/s11899-021-00635-3 · DOI
- Jayaraman, 2019, Cut-Price CAR-T Cell Therapies Top India's Biotech Agenda, Nat Biotechnol, 37, 10.1038/s41587-019-0346-1 · DOI
- Lin, 2019, Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma, J Clin Oncol, 37, 10.1200/JCO.18.02079 · DOI · Paper page
- Pfeiffer, 2018, In Vivo Generation of Human CD19-CAR T Cells Results in B-Cell Depletion and Signs of Cytokine Release Syndrome, EMBO Mol Med, 10, 10.15252/emmm.201809158 · DOI · Paper page
- Agarwal, 2019, In Vivo Generated Human CAR T Cells Eradicate Tumor Cells, Oncoimmunology, 8, 10.1080/2162402X.2019.1671761 · DOI · Paper page
- Huckaby, 2021, Bispecific Binder Redirected Lentiviral Vector Enables In Vivo Engineering of CAR-T Cells, J Immunother Cancer, 9, 10.1136/jitc-2021-002737 · DOI
- Nawaz, 2021, AAV-Mediated In Vivo CAR Gene Therapy for Targeting Human T-Cell Leukemia, Blood Cancer J, 11, 119, 10.1038/s41408-021-00508-1 · DOI · Paper page
- Santoiemma, 2015, Tumor Infiltrating Lymphocytes in Ovarian Cancer, Cancer Biol Ther, 16, 10.1080/15384047.2015.1040960 · DOI · Paper page
- Siegler, 2018, Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy, Hum Gene Ther, 29, 10.1089/hum.2017.243 · DOI
- Agliardi, 2021, Intratumoral IL-12 Delivery Empowers CAR-T Cell Immunotherapy in a Pre-Clinical Model of Glioblastoma, Nat Commun, 12, 444, 10.1038/s41467-020-20599-x · DOI · Paper page
- Mollanoori, 2018, CRISPR/Cas9 and CAR-T Cell, Collaboration of Two Revolutionary Technologies in Cancer Immunotherapy, an Instruction for Successful Cancer Treatment, Hum Immunol, 79, 10.1016/j.humimm.2018.09.007 · DOI
- Salas-Mckee, 2019, CRISPR/Cas9-Based Genome Editing in the Era of CAR T Cell Immunotherapy, Hum Vaccin Immunother, 15, 10.1080/21645515.2019.1571893 · DOI
- Dai, 2019, Standardizing CAR-T Therapy: Getting it Scaled Up, Biotechnol Adv, 37, 10.1016/j.biotechadv.2018.12.002 · DOI
- Ho, 2019, Dissection of Gastric Cancer Heterogeneity for Precision Oncology, Cancer Sci, 110, 10.1111/cas.14191 · DOI
Cited by
Picht, S., Farrera-Sal, M., Hiller, A. L., Brumhard, S., Klaas, A. M., Schulenberg, S., Friedrich, R., Scholz, C., Hemmerling, L., Simon, D. N., et al. (2026) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2026.102929 · Cited by 7
Metadata
- Authors
- Xin, T., Cheng, L., Zhou, C., Zhao, Y., Hu, Z., & Wu, X.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2022-02-10
- Volume
- 12
- ISSN
- 2234-943X
- Cited by
- 110
- References
- 20
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.